Mirati Therapeutics Inc.
(NASDAQ : MRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.45%185.151.2%$602.67m
CELGCelgene Corporation
-0.43%78.801.2%$532.62m
GILDGilead Sciences, Inc.
-0.63%71.070.9%$518.63m
BIIBBiogen Inc.
-0.44%296.041.2%$437.32m
NKTRNektar Therapeutics
-5.39%52.855.6%$412.99m
SRPTSarepta Therapeutics, Inc.
-6.23%140.3316.6%$356.37m
VRTXVertex Pharmaceuticals Incorporated
1.67%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.89%331.972.6%$248.01m
ILMNIllumina, Inc.
-1.19%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-9.85%168.9015.7%$194.29m
EXASExact Sciences Corporation
-3.62%66.3325.4%$180.98m
AAgilent Technologies, Inc.
-0.40%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
1.40%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.61%99.034.4%$141.99m
INCYIncyte Corporation
2.12%74.032.5%$133.28m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.